References
- Di Perri T., Laghi, Pasini F., Capecchi P. L., Blardi P., Pasqui A. L., Franchi M., Mazza S., Sodi N., Domini L., Ceccatelli L., Volpi L. Pharmacodynamics of salmon calcitonin in humans: New markers of pharmacological activity. Eur. J. Clin. Pharmacol. 1992; 43: 229–233
- Dua R., Zia H., Needham T. E. Effect of formulation and device variables on nasal spray delivery. Pharm. Res. 1995; 11: S–211
- Dua R., Zia H., Needham T. E. The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits. Int. J. Pharm. 1997; 147: 233–242
- Epand R. M., Epand R. F., Orlowski R. F., Schlueter R. J., Boni L. T., Hui S. W. Amphipathic helix and its relationship to the interaction of calcitonin with phospholipids. Biochemistry 1983; 22: 5074–5084
- Epand R. M., Epand R. F., Stafford A. R., Orlowski R. C. Deletion sequences of salmon calcitonin that retain the essential biological and conformational features of the intact molecule. J. Med. Chem. 1988; 31: 1595–1598
- Epand R. M., Epand R. F., Orlowski R. C. Presence of an amphipathic helical segment and its relationship to biological potency of calcitonin analogs. Int. J. Peptide Protein Res. 1993b; 25: 105–111
- Epand R., Epand R. F., Orlowski R. C., Flanigan Stahl Everett, Glenn L. A. A comparison of the interaction of glucagon, human parathyroid hormone-(1–3–4)-peptide and calcitonin with dimyristoylphosphatidylglycerol and with dimyristoylphosphatidylcholine. Biophys. Chem. 1993a; 23: 39–48
- Harris A. S., Ohlin M., Svensson E., Lethagen S., Nilsson I. M. Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J. Pharm. Sci. 1988; 77: 337–339
- Harris A. S., Ohlin M., Svensson E., Lethagen S., Nilsson I. M. Effects of viscosity on the pharmacokinetics and biological response to intranasal desmopressin. J. Pharm. Sci. 1992; 81: 470–471
- Hirai S., Yashiki T., Mima H. Effect of surfactants on the nasal absorption on insulin on rats. J. Pharm. Sci. 1981; 9: 165–172
- Ilium L., Farraj N., Davis F., Johanssen S. S.B. R., O'Hagen D. T. Investigation of the nasal absorption of biosynthetic human growth in sheep-use of a bioadhesive microsphere delivery system. Int. J Pharm. 1990; 63: 207–211
- Jager-Waldau R. A two phase flow mechanical spray pump: A possible alternative to propellant driven MDI's. J. Biopharm. Sci. 1992; 3: 77–84
- Lee W. A. Permeation enhancers for the nasal delivery of protein and peptide therapeutics. Biopharmaceutics 1990; 3: 22
- Levy R. S. Efficient calcitonin production. Biopharmaceutics 1993; 36–39, May
- Morimoto K., Morisaka K., Kamada. Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel. J. Pharm. Pharmacol. 1985; 37: 134–136
- O'Hagan D. T., Critchley H., Farraj N. F., Johansen B. R., Davis S. S., Ilium L. Effects of various absorption enhancers on the nasal absorption of biosynthetic human growth hormone in the rat. Pharm. Res. 1990; 7: 772–776
- Stafford R. E., Dennis E. A. Lysophospholipids as biosurfactants. Colloids and Surfaces 1988; 30: 47–64
- Tagesson C., Franzen L., Dahl G., Westrom B. Lysophosphatidylcholine increases rat ileal permeability to macromolecules 1985; 26: 369–377
- Ziegler R., Holz G., Strebbl W., Raue R. Nasal applications of calcitonin in Paget's disease of bone. Acta Endoac. Suppl. 1978; 215: 54–55